PDCD1 and neoplasm: PD-L1 immunohistochemistry correlates with treatment response, particularly in advanced disease where PD-L1 tumour proportion score (TPS) ≥ 50% is associated with higher response rates and improved survival with single agent anti-PD-1 pembrolizumab compared to chemotherapy [1].